← back to search

Samuel L.M. Arnold

University of Washington · US
Area of research
Cancer Research · Parasitology
Research interest
Research interests include Cancer, Lipids, and Metabolism, Cancer, Hypoxia, and Metabolism, Biological Research and Disease Studies, and Parasitic Infections and Diagnostics.
h-index
24
citations
1,628
works
172
NIH funding
primary concept
email

Recent publications

Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned
International Journal for Parasitology 2020cited by 49position: middledoi
One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases
Veterinary Parasitology 2020cited by 32position: middledoi
Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy
The Journal of Infectious Diseases 2017cited by 67position: middledoi
Extended-spectrum antiprotozoal bumped kinase inhibitors: A review
Experimental Parasitology 2017cited by 64position: middledoi
Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection
The Journal of Infectious Diseases 2017cited by 60position: firstdoi
Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis
International Journal for Parasitology 2017cited by 39position: middledoi
Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis
The Journal of Infectious Diseases 2016cited by 73position: middledoi
Altered Expression of Small Heterodimer Partner Governs Cytochrome P450 (CYP) 2D6 Induction during Pregnancy in CYP2D6-humanized Mice
Journal of Biological Chemistry 2013cited by 52position: middledoi
Nitric Oxide and Interleukin-1β Stimulate the Proteasome-Independent Degradation of the Retinoic Acid Hydroxylase CYP2C22 in Primary Rat Hepatocytes
Journal of Pharmacology and Experimental Therapeutics 2013cited by 22position: middledoi
Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance
Anti-Cancer Agents in Medicinal Chemistry 2012cited by 50position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael W. Riggs · University of Arizona4 papers (2016–2017)Matthew A. Hulverson · Seattle University4 papers (2016–2017)Dustin J. Maly · Seattle University4 papers (2016–2017)Wesley C. Van Voorhis · Infectious Disease Research Institute4 papers (2016–2017)Kayode K. Ojo · Seattle University4 papers (2016–2017)Lynn K. Barrett · Seattle University3 papers (2016–2017)Deborah A. Schaefer · University of Arizona3 papers (2016–2017)Erkang Fan · Seattle University3 papers (2016–2017) · 3 papers (2016–2017)Ryan Choi · Palo Alto University3 papers (2017–2017)Nina Isoherranen · University of Washington2 papers (2013–2013)Dana P. Betzer · University of Arizona2 papers (2016–2017)Sumiti Vinayak · University of Illinois Urbana-Champaign2 papers (2017–2017)Grant R. Whitman · Seattle University2 papers (2017–2017)Wenlin Huang · Seattle University2 papers (2016–2017) · 2 papers (2016–2017)Boris Striepen · Medivis (Italy)2 papers (2017–2017)Choon M. Lee · Emory University1 papers (2013–2013)Sylvia S. Gayle · National Cancer Institute1 papers (2012–2012)Hayley Sparks · The University of Texas Medical Branch at Galveston1 papers (2017–2017)